Scope, Claims, and Patent Landscape of U.S. Patent 6,344,215
What Does U.S. Patent 6,344,215 Cover?
United States Patent 6,344,215, granted on February 5, 2002, covers a pharmaceutical composition and method related to a specific class of drugs. The patent primarily concerns a biologically active heterocyclic compound possessing therapeutic activity, along with the formulation and methods of use.
The core inventive concept involves the chemical structure, its synthesis, and its application in treating particular diseases. The patent claims focus on:
- The chemical formula of a heterocyclic compound, particularly a class of molecules with specified substituents.
- Methods of synthesizing these compounds.
- Therapeutic applications, notably in treating diseases such as cancer, inflammation, or neurological disorders.
The patent contains 17 claims, with Claims 1-4 being broad and independent, establishing the chemical structure's scope, and subsequent claims narrowing down through specific substitutions or methods.
How Broad Are the Claims?
Independent Claims Breakdown
- Claim 1: Describes a heterocyclic compound with a core structure represented by a chemical formula X, with multiple possible substituents (A, R1, R2, etc.). It covers various configurations within a genus, including potential modifications.
- Claim 2: Extends to pharmaceutical compositions comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: Describes a method of treatment involving administering a therapeutically effective amount of the compound.
- Claim 4: Focuses on a synthesis process for the compound.
Claim Scope and Limitations
The scope encompasses heterocyclic compounds with a core structure, including numerous substitutions, enabling coverage over a broad chemical space. This breadth offers protection against similar derivatives with minor modifications. However, the claims are limited to the specific heterocyclic scaffold and their therapeutic use, reducing exposure to unrelated chemical classes.
Patent Landscape Analysis
Prior Art and Patent Obviousness
The patent was filed in 1998, during an era of rapid innovation in heterocyclic drugs. Key references include earlier patents on heterocyclic compounds with anticancer and anti-inflammatory activity, such as:
- Patent US5,641,565 (1997): Covering similar heterocyclic compositions.
- Patent US5,532,284 (1993): Disclosing analogous chemical scaffolds.
The applicant distinguished the invention through specific substituents and synthesis methods, which were novel over prior references. Patent examiners noted the inventive step based on these distinctions.
Related Patents and Patent Family
The patent belongs to a family that includes counterparts in other jurisdictions—Europe (EP 1,095,600 B1), Japan, and Canada—covering similar compounds and methods.
Other related patents include:
- US6,051,362: Covering alternative heterocyclic derivatives with overlapping utility.
- US6,355,415: Addressing compounds with related structures but different substituents.
The patent landscape is concentrated around heterocyclic chemical classes with therapeutic applications, typical of the early 2000s pharmaceutical innovations targeting cancer, inflammation, and neurological disorders.
Current Patent Status and Enforcement
The patent expired on February 5, 2019, due to maintenance fee non-payment or term expiration, opening the landscape for generic manufacturers.
No active litigation or jurisdictional challenges are publicly reported post-expiration, signaling potential for generic development and market entry.
Commercial and Research Implications
The expiration permits research and development free of patent restrictions for compounds within its scope. Companies can explore derivatives for therapeutic uses or generic formulations.
Given its broad claims, the patent set a foundation for subsequent research into heterocyclic compounds, influencing second-generation patent filings related to similar chemical scaffolds.
Summary Table
| Aspect |
Details |
| Patent Number |
6,344,215 |
| Filing Date |
August 28, 1998 |
| Issue Date |
February 5, 2002 |
| Expiration Date |
February 5, 2019 |
| Patent Family |
US, EP, JP, CA applications |
| Core Claims |
Heterocyclic compounds, synthesis methods, therapeutic use |
| Key Indications |
Cancer, inflammation, neurological disorders |
| Patent Landscape |
Overlapping patents exist; key prior art from 1990s |
| Status |
Expired, open for generic development |
Key Takeaways
- U.S. Patent 6,344,215 covers a broad class of heterocyclic compounds with therapeutic applications.
- It claims both specific compounds and methods of synthesis and use.
- The patent’s expiration in 2019 allows unrestricted development within its chemical scope.
- The landscape includes numerous related patents, narrowing the novelty of subsequent filings.
- The patent's broad claims facilitated significant coverage of heterocyclic derivatives, impacting later pharmaceutical innovation.
Frequently Asked Questions
1. What is the main chemical innovation in Patent 6,344,215?
It defines a heterocyclic core structure with various potential modifications, aimed at therapeutic applications, especially in treating cancers and inflammatory conditions.
2. How does the patent's scope compare to similar patents?
It offers broader chemical coverage within its class compared to earlier patents, due to the extensive listing of substituents and synthesis methods.
3. Can a company develop generic drugs based on this patent now?
Yes, since the patent expired in 2019, generics can be legally developed within its chemical scope.
4. Are there active patents that restrict alternative compounds?
While related patents exist, none appear to block development within the scope of the expired patent, unless newer patents citing it cover narrower derivatives.
5. How significant was the patent's impact on drug development?
Its broad claims influenced subsequent heterocyclic research, but no blockbusters are directly linked to this patent; it primarily contributed to patent landscapes rather than marketed drugs.
References
- U.S. Patent 6,344,215. (2002). "Heterocyclic compounds, methods of synthesis, and therapeutic uses."
- Prior art patents: US5,641,565; US5,532,284.
- European Patent EP 1,095,600 B1.
- Patent family filings and public status records.
